There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Cytokinetics (CYTK – Research Report) and Senti Biosciences (SNTI – Research Report) with bullish sentiments.
Cytokinetics (CYTK)
In a report released today, Salim Syed from Mizuho Securities maintained a Buy rating on Cytokinetics, with a price target of $80.00. The company’s shares closed last Thursday at $39.12.
According to TipRanks.com, Syed has 0 stars on 0-5 stars ranking scale with an average return of
Cytokinetics has an analyst consensus of Strong Buy, with a price target consensus of $74.33, a 94.6% upside from current levels. In a report issued on November 4, Needham also maintained a Buy rating on the stock with a $60.00 price target.
See today’s best-performing stocks on TipRanks >>
Senti Biosciences (SNTI)
Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Senti Biosciences today and set a price target of $12.00. The company’s shares closed last Thursday at $2.48, close to its 52-week low of $1.20.
According to TipRanks.com, Livshits is a 5-star analyst with an average return of
Senti Biosciences has an analyst consensus of Moderate Buy, with a price target consensus of $8.83.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on CYTK:
